{"name":"Keith Edwards, M.D.","slug":"keith-edwards-m-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cladribine Tablets","genericName":"Cladribine Tablets","slug":"cladribine-tablets","indication":"Hairy cell leukemia","status":"marketed"}]}],"pipeline":[{"name":"Cladribine Tablets","genericName":"Cladribine Tablets","slug":"cladribine-tablets","phase":"marketed","mechanism":"Cladribine is a purine nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing selective depletion of lymphocytes.","indications":["Hairy cell leukemia","Multiple sclerosis (relapsing forms)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}